Exclusive Video Marketing Software for Startups 

YishengBio Raises $130M in Series B Funding

YishengBio Co., Ltd., a Beijing, China-based fully integrated biopharmaceutical company, closed a US$130m Series B funding round. After completing the Series B funding round, the company’s institutional investors include: OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International, etc. YishengBio’s YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China. The rabies vaccine has been commercialized in China and has served over 16 million patients for post-exposure protection against rabies. Being able to accelerate post-exposure immune protection,PIKA rabies vaccine has the potential to lead in the rabies vaccines market in the future.

Startup Around is now on Telegram and Whatsapp. For the best startup stories & resources, subscribe us on Telegram & Whatsapp.
World-class video marketing software for startups